{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-014296","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2025-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.568620+00:00","generated_at":"2026-05-19T17:35:26.526665+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"FibroBiologics appoints Jason D. Davis, CPA, as CFO; base salary $350k","bullets":["Jason D. Davis appointed CFO effective June 9, 2025; previously CFO at Virax Biolabs, led IPO in July 2022.","Employment agreement includes base salary of $350k, annual bonus up to 40% of base, and sign-on cash bonus of $15k.","Received option grant of 450,000 shares under 2022 Stock Plan; vests 1/4 on first anniversary, then monthly.","Davis has 20+ years finance experience; at HyperDynamics increased market cap from $20M to $700M and raised $200M+.","Appointment comes as FibroBiologics advances toward Phase 1/2 clinical trial for diabetic foot ulcers in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-014296","json":"https://secwatch.observer/filing/0001641172-25-014296.json","markdown":"https://secwatch.observer/filing/0001641172-25-014296.md","text":"https://secwatch.observer/filing/0001641172-25-014296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000164117225014296/0001641172-25-014296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000164117225014296/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T17:35:26.526665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3053b4aef0","claim":"Jason D. Davis was appointed as Chief Financial Officer at FibroBiologics, Inc..","evidence_excerpt":"On June 9, 2025, FibroBiologics, Inc. (the “Company”) announced that Jason D. Davis has been appointed as the Company’s Chief Financial Officer, effective as of June 9, 2025 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000164117225014296/0001641172-25-014296-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}